IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023